Back

Analysts identify catalysts across CSPC, Raffles Medical and Manipal Health

Verifying
  • Analysts issued positive views on CSPC Pharmaceutical, Raffles Medical and Manipal Health Enterprises.
  • CSPC trades at 18X 2027 earnings, about 28% below its peer average.
  • Jefferies forecasts Manipal revenue and EBITDA growth of 17% and 19% annually.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.